C
Charla Andrews
Researcher at Walter Reed Army Institute of Research
Publications - 19
Citations - 3532
Charla Andrews is an academic researcher from Walter Reed Army Institute of Research. The author has contributed to research in topics: Antibody & AIDSVAX. The author has an hindex of 14, co-authored 16 publications receiving 3259 citations. Previous affiliations of Charla Andrews include Henry M. Jackson Foundation for the Advancement of Military Medicine & University of Massachusetts Medical School.
Papers
More filters
Journal ArticleDOI
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Barton F. Haynes,Peter B. Gilbert,M. Juliana McElrath,Susan Zolla-Pazner,Georgia D. Tomaras,S. Munir Alam,David T. Evans,David C. Montefiori,Chitraporn Karnasuta,Ruengpueng Sutthent,Hua-Xin Liao,Anthony L. DeVico,George K. Lewis,Constance Williams,Abraham Pinter,Youyi Fong,Holly Janes,Allan C. deCamp,Yunda Huang,Mangala Rao,Erik Billings,Nicos Karasavvas,Merlin L. Robb,Viseth Ngauy,Mark de Souza,Robert Paris,Guido Ferrari,Robert T. Bailer,Kelly A. Soderberg,Charla Andrews,Phillip W. Berman,Nicole Frahm,Stephen C. De Rosa,Michael D. Alpert,Nicole L. Yates,Xiaoying Shen,Richard A. Koup,Punnee Pitisuttithum,Jaranit Kaewkungwal,Sorachai Nitayaphan,Supachai Rerks-Ngarm,Nelson L. Michael,Jerome H. Kim +42 more
TL;DR: V vaccines that are designed to induce higher levels of V1V2 antibodies and lower levels of Env-specific IgA antibodies than are induced by the RV144 vaccine may have improved efficacy against HIV-1 infection.
Journal ArticleDOI
Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines
Amy W. Chung,Musie Ghebremichael,Hannah Robinson,Eric P. Brown,Ickwon Choi,Sophie Lane,Anne-Sophie Dugast,Matthew K. Schoen,Morgane Rolland,Todd J. Suscovich,Alison E. Mahan,Larry Liao,Hendrik Streeck,Charla Andrews,Supachai Rerks-Ngarm,Sorachai Nitayaphan,Mark de Souza,Jaranit Kaewkungwal,Punnee Pitisuttithum,Donald P. Francis,Nelson L. Michael,Jerome H. Kim,Chris Bailey-Kellogg,Margaret E. Ackerman,Galit Alter +24 more
TL;DR: The human phase 2B RV144 ALVAC-HIV vCP1521/AIDSVAX B/E vaccine trial, held in Thailand, resulted in an estimated 31.2% efficacy against HIV infection as discussed by the authors.
Journal ArticleDOI
Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials
David C. Montefiori,Chitraporn Karnasuta,Ying Huang,Hasan Ahmed,Peter B. Gilbert,Mark de Souza,Robert McLinden,Sodsai Tovanabutra,Agnes Laurence-Chenine,Eric Sanders-Buell,M. Anthony Moody,Mattia Bonsignori,Christina Ochsenbauer,John C. Kappes,Haili Tang,Kelli Greene,Hongmei Gao,Celia C. LaBranche,Charla Andrews,Victoria R. Polonis,Supachai Rerks-Ngarm,Punnee Pitisuttithum,Sorachai Nitayaphan,Jaranit Kaewkungwal,Steve Self,Phillip W. Berman,Donald P. Francis,Faruk Sinangil,Carter Lee,Jim Tartaglia,Merlin L. Robb,Barton F. Haynes,Nelson L. Michael,Jerome H. Kim +33 more
TL;DR: The results suggest either that weak neutralizing antibody responses can be partially protective against HIV-1 in low-risk heterosexual populations or that the modest efficacy seen in RV144 was mediated by other immune responses, either alone or in combination with neutralizing antibodies.
Journal ArticleDOI
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection
Susan Zolla-Pazner,Allan C. deCamp,Peter B. Gilbert,Constance Williams,Nicole L. Yates,William T. Williams,Robert Howington,Youyi Fong,Daryl E. Morris,Kelly A. Soderberg,Carmela Irene,Charles Reichman,Abraham Pinter,Robert Parks,Punnee Pitisuttithum,Jaranit Kaewkungwal,Supachai Rerks-Ngarm,Sorachai Nitayaphan,Charla Andrews,Robert J. O'Connell,Zhi Yong Yang,Gary J. Nabel,Jerome H. Kim,Nelson L. Michael,David C. Montefiori,Hua-Xin Liao,Barton F. Haynes,Georgia D. Tomaras +27 more
TL;DR: Levels of vaccine-induced IgG Abs recognizing V1V2 regions from multiple HIV-1 subtypes, and presented on different scaffolds constitute inverse correlates of risk for HIV- 1 infection in the RV144 vaccine trial.
Journal ArticleDOI
The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120
Nicos Karasavvas,Erik Billings,Mangala Rao,Constance Williams,Susan Zolla-Pazner,Robert T. Bailer,Richard A. Koup,Sirinan Madnote,Duangnapa Arworn,Xiaoying Shen,Georgia D. Tomaras,Jeffrey R. Currier,Mike Jiang,Craig A. Magaret,Charla Andrews,Raphael Gottardo,Peter B. Gilbert,Timothy Cardozo,Supachai Rerks-Ngarm,Sorachai Nitayaphan,Punnee Pitisuttithum,Jaranit Kaewkungwal,Robert Paris,Kelli Greene,Hongmei Gao,Sanjay Gurunathan,Jim Tartaglia,Faruk Sinangil,Bette T. Korber,David C. Montefiori,John R. Mascola,Merlin L. Robb,Barton F. Haynes,Viseth Ngauy,Nelson L. Michael,Jerome H. Kim +35 more
TL;DR: Early HIV-1 transmission events involve V2 loop interactions, raising the possibility that anti-V2 antibodies in RV144 may have contributed to viral inhibition.